Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04564989 |
Recruitment Status :
Recruiting
First Posted : September 25, 2020
Last Update Posted : April 17, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Oropharyngeal Squamous Cell Carcinoma Carcinoma, Squamous Cell Head and Neck Squamous Cell Carcinoma Oropharynx Squamous Cell Carcinoma |
Study Type : | Observational |
Estimated Enrollment : | 220 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | LCCC 2044: Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC |
Actual Study Start Date : | November 19, 2020 |
Estimated Primary Completion Date : | November 2033 |
Estimated Study Completion Date : | November 2033 |
Group/Cohort |
---|
HPV+ OPSCC Patients
Patients with p16+ squamous cell carcinoma of the oropharynx (or unknown primary) who will receive definitive cancer treatment.
|
- Recurrence of OPSCC [ Time Frame: From date of therapy completion until biopsy-proven recurrence, assessed up to 5 years ]Patients will undergo post-treatment CT scans per institutional standard of care to detect cancer recurrence. Status of recurrence of OPSCC will be confirmed based on biopsy.
- Progression-free survival [ Time Frame: From beginning or end of treatment until date of CT-detected recurrence or date of death, assessed up to 5 years ]Time-to-recurrence will be defined as time lapsed from end (or start) of treatment to first date recurrence (biopsy proven occur later) is detected by CT scans, or death. Otherwise, time-to-recurrence is censored at end of study date.
- Positive Predictive Value [ Time Frame: Baseline to up to 5 years ]Positive Predictive Value (PPV) is defined as probability that patients with two consecutive positive cHPVDNA (i.e., detectable cHPVDNA) really develop OPSCC recurrence during the study period.
- Negative Predictive Value [ Time Frame: Baseline to up to 5 years ]Negative Predictive Value (NPV) is defined as probability that patients without two consecutive positive cHPVDNA do not develop OPSCC recurrence during the study period.
- Quality of Life questionnaire [ Time Frame: Baseline until recurrence or up to 5 years ]At specified timepoints before, during, and after treatment, patients will complete a questionnaire comprised of questions from the European Organization for Research and Treatment of Cancer (EORTC) QLQ H&N35, which is for head and neck cancer patients, and EORTC QLQ C30, which is a general cancer assessment.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- ≥ 18 years of age
- T0-T2 N2a-N3 M0 or T3-T4 N0-N3 M0 (AJCC 7th edition)
- Biopsy proven squamous cell carcinoma of the oropharynx or unknown primary
- No prior therapy
- No evidence of distant metastatic disease
- p16 positive = diffuse ≥ 70% tumor cell expression, with at least moderate (2/3+) staining intensity
- Planned for receipt of definitive cancer treatment
- ECOG Performance Status 0-1
- Patients must be deemed able to comply with the treatment plan and follow-up schedule.
- Patients must provide study specific informed consent prior to study entry
Exclusion Criteria: All subjects meeting any of the exclusion criteria at baseline will be excluded from study participation:
- Prior history of radiation therapy to the head and neck
- Prior history of head and neck cancer.
- Inadequate pre-treatment tissue sample for tumor genomic analyses
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04564989
Contact: Chris Hilliard | 919-966-4432 | chris_hilliard@med.unc.edu | |
Contact: Wendell Yarbrough, MD | 919-843-7091 | dell@med.unc.edu |
United States, Minnesota | |
Mayo Clinic | Recruiting |
Rochester, Minnesota, United States, 55905 | |
Contact: Dan Ma, MD 507-284-8227 ma.daniel@mayo.edu | |
United States, North Carolina | |
University of North Carolina at Chapel Hill | Recruiting |
Chapel Hill, North Carolina, United States, 27599 | |
Contact: Chris Hilliard 919-966-4432 chris_hilliard@med.unc.edu | |
Principal Investigator: Wendell Yarbrough, MD |
Principal Investigator: | Wendell Yarbrough, MD | UNC Chapel Hill |
Responsible Party: | UNC Lineberger Comprehensive Cancer Center |
ClinicalTrials.gov Identifier: | NCT04564989 |
Other Study ID Numbers: |
LCCC 2044 1U01DE029754-01 ( U.S. NIH Grant/Contract ) |
First Posted: | September 25, 2020 Key Record Dates |
Last Update Posted: | April 17, 2024 |
Last Verified: | March 2024 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Human Papillomavirus HPV p16 Oropharynx OPSCC |
Carcinoma Carcinoma, Squamous Cell Squamous Cell Carcinoma of Head and Neck Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |
Neoplasms Neoplasms, Squamous Cell Head and Neck Neoplasms Neoplasms by Site |